Skip to main content

Advertisement

Log in

Iron Deficiency in Women’s Health: New Insights into Diagnosis and Treatment

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Iron deficiency (ID), with or without anemia, is commonly found worldwide and affects the health and wellbeing of pregnant and nonpregnant women. Symptoms of ID- which include fatigue, pica (ice craving), restless legs syndrome, poor concentration and work function, increased susceptibility to infection, and cardiovascular stress- can cause significant morbidity and reduced quality of life. The etiologies of iron deficiency in women are usually specific to each community. In the developing world, iron deficiency is usually associated with poor iron intake and parasitic infections, whereas in higher income regions, iron deficiency is typically the result of heavy, abnormal uterine bleeding, and pregnancy. Iron-poor diets and poor iron absorption resulting from gut disorders can also play a role. Diagnosis of iron deficiency is usually straightforward and characterized by a low ferritin level; however, the diagnosis can be challenging in women with concomitant inflammatory disorders, in which case a low percent transferrin saturation, performed after an overnight fast, can inform on the need for iron. Therapy is frequently initiated with oral iron salts; however, use of these oral regimens is commonly associated with adverse events, mostly gastrointestinal in nature, that have been shown to adversely impact compliance, continuation, and the achievement of therapeutic goals. A further impediment to the effectiveness of oral iron is its poor absorption because of comorbidity (i.e., celiac disease, gastritis, etc.), surgery (bariatric), or physiologic inhibitory mechanisms. As such, intravenous (IV) iron regimens are increasingly being used to treat ID, as such regimens have been shown to avoid the gastrointestinal adverse events commonly associated with oral regimens. Indeed, IV iron has been shown to provide adequate iron replacement in women with functional iron deficiencies as well as those with ID resulting from inflammatory disorders- patients often resistant to oral iron therapy. More recent IV iron regimens have been shown to provide iron replacement in a safe and effective manner, being associated with more salutary adverse event profiles than earlier IV iron regimens. In fact, these iron regimens can provide a complete replacement dose in a single 15–60-min visit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica. 2020;105(2):260–72.

    Article  Google Scholar 

  2. Kassebaum NJ, Jasrasaria R, Naghavi M, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123:615–24.

    Article  CAS  Google Scholar 

  3. Camaschella C. Iron deficiency: new insights into diagnosis and treatment. Hematol Am Soc Hematol Educ Program. 2015;2015:8–13.

    Article  Google Scholar 

  4. Daru J, Cooper NA, Khan KS. Systematic review of randomized trials of the effect of iron supplementation on iron stores and oxygen-carrying capacity in pregnancy. Acta Obstet Gynecol Scand. 2016;95:270–9.

    Article  CAS  Google Scholar 

  5. Percy L, Mansour D, Fraser I. Iron deficiency and iron-deficiency anemia in women’s health. Best Pract Res Clin Obstet Gynaecol. 2017;40:55–67.

    Article  Google Scholar 

  6. Muñoz M, Villar I, García-Erce JA. An update on iron physiology. World J Gastroenterol. 2009;15:4617–26.

    Article  Google Scholar 

  7. Zhao L, Zhang X, Shen Y, et al. Obesity and iron deficiency: a quantitative meta-analysis. Obes Rev. 2015;16:1081–93.

    Article  CAS  Google Scholar 

  8. Cepeda-Lopez AC, Aeberli I, Zimmermann MB. Does obesity increase risk for iron deficiency? A review of the literature and the potential mechanisms. Int J Vit Nutr Res. 2010;80:263–70.

    Article  CAS  Google Scholar 

  9. Wessling-Resnick M. Iron homeostasis and the inflammatory response. Annu Rev Nutr. 2010;30:105–22.

    Article  CAS  Google Scholar 

  10. D’Angelo G. Role of hepcidin in the pathophysiology and diagnosis of anemia. Blood Res. 2013;48:10–5.

    Article  Google Scholar 

  11. Nairz M, Theurl I, Wolf D, Weiss G. Iron deficiency or anemia of inflammation? Wien Med Wochenschr. 2016;166:411–23.

    Article  Google Scholar 

  12. Breymann C, Auerbach M. Iron deficiency in gynecology and obstetrics: clinical implications and mananagement. Hematol Am Soc Hematol Educ Program. 2017;8:152–9.

    Article  Google Scholar 

  13. Mahey R, Kriplani A, Mogili KD, et al. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding. Int J Gynaecol Obstet. 2016;133:43–8.

    Article  CAS  Google Scholar 

  14. Ferrara M, Coppola L, Coppola A, Caprizzi M. Iron deficiency in childhood and adolescence: retrospective review. Hematology. 2006;11:183–6.

    Article  CAS  Google Scholar 

  15. Whitaker L, Critchley HOD. Abnormal uterine bleeding. Best Pract Res Clin Obstet Gynaecol. 2016 Jul;34:54–65.

    Article  Google Scholar 

  16. Magnay JL, O’Brien S, Gerlinger C, Seitz C. A systematic review of methods to measure menstrual blood loss. BMC Women’s Health. 2018;18:142–55.

    Article  Google Scholar 

  17. Munro MG, Critchley HOD, Broder MS, et al. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113:3–13.

    Article  Google Scholar 

  18. El-Andaloussi A, Chaudhry Z, Al-Hendy A, et al. Uterine fibroids: Bridging genomic defects and chronic inflammation. Semin Reprod Med. 2017;35:494–8.

    Article  CAS  Google Scholar 

  19. Jimenez JM, Gache C. Management of iron deficiency anaemia in inflammatory bowel disease. Acta Haematol. 2019;142:30–6.

    Article  CAS  Google Scholar 

  20. Georgieff MK. Iron deficiency in pregnancy. Am J Obstet Gynecol. 2020;223(4):516–24.

    Article  CAS  Google Scholar 

  21. Miller JL. Iron deficiency anemia: a common and curable disease. Cold Spring Harb Perspect Med. 2013;3:a011866.

    Article  Google Scholar 

  22. Milman N. Postpartum anemia I: definition, prevalence, causes and consequences. Ann Hematol. 2011;90:1247–53.

    Article  Google Scholar 

  23. Milman N. Postpartum anemia II: prevention and treatment. Ann Hematol. 2012;91:143–54.

    Article  CAS  Google Scholar 

  24. Gomez-Ramirez S, Bisbe E, Shander A, et al. Management of perioperative iron deficiency anemia. Acta Haematol. 2019;142:21–9.

    Article  CAS  Google Scholar 

  25. Pratt JJ, Khan KS. Non-anemic iron deficiency—a disease looking looking for recognition of diagnosis: a systematic review. Eur J Haemotol. 2015;96:618–28.

    Article  Google Scholar 

  26. Onken JE, Bregman DB, Harrington RA, et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion. 2014;54:306–15.

    CAS  PubMed  Google Scholar 

  27. Stoffel N., Cercamondi C, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol 2017; E524-E533

  28. Onken JE, Bregman DB, Harrington RA, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transpl. 2014;29:833–42.

    Article  CAS  Google Scholar 

  29. Adkinson NF, Strauss WE, Macdougall IC, et al. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: a randomized trial. Am J Hematol. 2018;93:683–90.

    Article  CAS  Google Scholar 

  30. Van Wyck DB, Mangione A, Morrison J, et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009;49:2719–28.

    Article  Google Scholar 

  31. Seid MH, Butcher AD, Chatwani A. Ferric carboxymaltose as treatment in women with iron-deficiency anemia. Anemia. 2017;2017:9642027. https://doi.org/10.1155/2017/9642027.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Camaschella C. Iron deficiency anemia. N Engl J Med. 2015;372:1832–43.

    Article  Google Scholar 

  33. Girelli D, Ugolini S, Busti F, et al. Modern iron replacement therapy: clinical and pathophysiological insights. Int J Hematol. 2018;107:16–30.

    Article  CAS  Google Scholar 

  34. Kim YH, Ching HH, Kang S-B, et al. Safety and usefulness of intravenous iron sucrose in the management of preoperative anemia in patients with menorrhagia: a phase IV, open-label, prospective, randomized study. Acta Haematol. 2009;121:37–41.

    Article  CAS  Google Scholar 

  35. Lee S, Ryu KJ, Lee ES, et al. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for the treatment of preoperative anemia in patients with menorrhagia: an open-label, multicenter, randomized study. J Obstet Gynaecol Res. 2019;45:858–64.

    Article  CAS  Google Scholar 

  36. Auerbach M, Henry D, Derman RJ, et al. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am J Hematol. 2019;94:1007–14.

    Article  CAS  Google Scholar 

  37. Wolf M, Auerbach M, Kalra PA. Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: the FERWON-IDA/NEPHRO trials. Am J Hematol. 2021;96:E11–5.

    Article  CAS  Google Scholar 

  38. Wang C, Graham DJ, Kane RC, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA. 2015;314:2062–8.

    Article  CAS  Google Scholar 

  39. DeLoughery TG. Safety of oral and intravenous iron. Acta Haematol. 2019;142:8–12.

    Article  CAS  Google Scholar 

  40. Freidman AJ, Shander A, Martin SR, et al. Iron deficiency anemia in women: a practical guide to detection, diagnosis, and treatment. Obstet Gynecol Surv. 2015;70:342–53.

    Article  Google Scholar 

  41. DeLoughery TG. Iron deficiency anemia. Med Clin North Am. 2017;101:319–32.

    Article  Google Scholar 

  42. Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc. 2015;90:12–23.

    Article  Google Scholar 

Download references

Acknowledgements

Funding

No funding or sponsorship was received for publication of this article.

Author contributions

Dr. Shulman and Dr. Moisidis-Tesch contributed equally to concept and design, writing, and editing.

Disclosures

Dr. Shulman and Dr. Moisidis-Tesch both have nothing to disclose.

Compliance with ethics guidelines

This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by the authors.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Christina M. Moisidis-Tesch.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moisidis-Tesch, C.M., Shulman, L.P. Iron Deficiency in Women’s Health: New Insights into Diagnosis and Treatment. Adv Ther 39, 2438–2451 (2022). https://doi.org/10.1007/s12325-022-02157-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-022-02157-7

Keywords

Navigation